Defense Peptide Nanoparticles Deliver Gene-Silencing Therapy and Boost Immune Response Against Breast Cancer | Research

The takeaway

Cholesterol-modified defense peptide nanoparticles simultaneously delivered gene-silencing siRNA to breast cancer cells and stimulated anti-tumor immunity, suppressing tumor growth and invasion in preclinical models.

Dual-function platform
The HH2 defense peptide serves as both an efficient siRNA delivery vehicle and an immunostimulatory agent, combining gene silencing with immune activation against breast cancer

What the researchers found

The engineered HH2-siEMP2 nanoparticles achieved effective EMP2 gene silencing in breast cancer cells, leading to significant suppression of tumor migration and invasion both in vitro and in vivo.

Beyond direct anti-tumor effects, the HH2-cholesterol conjugate demonstrated immunomodulatory properties: promoting Th1 cell expansion (pro-inflammatory, anti-tumor), reducing Th2 cells (which can promote tumor tolerance), decreasing immunosuppressive regulatory T cells (Tregs), and restoring the Th17/Treg balance. The nanoparticles showed optimal size, positive surface charge, excellent serum stability, and enhanced cellular uptake.

Why it matters

Getting gene therapy into cancer cells effectively remains one of the biggest challenges in oncology. This study solves two problems at once: the defense peptide not only delivers the therapeutic cargo efficiently but also activates anti-cancer immunity — turning the delivery vehicle itself into part of the treatment. This dual-function approach could make gene-based cancer therapies more potent and practical.

How the study worked

Defense peptide HH2 was conjugated with cholesterol to form self-assembling nanoparticles that encapsulate EMP2-targeting siRNA. The nanoparticles were characterized for size, surface charge, and serum stability. Cellular uptake and EMP2 silencing efficacy were assessed in breast cancer cell lines. Anti-tumor effects (migration, invasion) were evaluated in vitro and in vivo in animal models. Immune cell profiling (Th1, Th2, Th17, Treg populations) assessed the immunomodulatory properties.

What this study cannot tell us

This is a preclinical study using cell lines and animal models. Clinical translation would need to address peptide stability, potential immunogenicity, and scalable manufacturing of the nanoparticles. The specific breast cancer subtypes and clinical contexts where this approach would be most effective are not yet defined. Long-term safety and pharmacokinetics were not characterized.

How to read the evidence

This is a preclinical study demonstrating proof-of-concept with in vitro and in vivo evidence. While the results are promising and the dual-function approach is novel, no human studies have been conducted.

When this study was published

Published in 2025, this study represents the cutting edge of peptide-based nanomedicine for cancer immunogene therapy.

The bigger picture

This study exemplifies the growing field of peptide-based nanomedicine, where antimicrobial or defense peptides are repurposed for cancer therapy. The combination of siRNA delivery with inherent immunostimulatory activity in a single peptide platform could inspire similar dual-function designs for other cancers and therapeutic targets, moving beyond the traditional view of peptides as either drugs or carriers, but not both.

Questions still open

Could this dual-function peptide nanoparticle platform be adapted to deliver siRNA targeting other cancer-related genes?
How does the immunomodulatory effect of the HH2 peptide compare to dedicated immunotherapy approaches like checkpoint inhibitors?
Would combining this peptide-based approach with existing breast cancer treatments produce synergistic effects?

Common questions

What makes this peptide approach different from other cancer treatments?

Most drug delivery systems are inert carriers — they transport the therapy but don't contribute to treatment themselves. This defense peptide carrier is different because it simultaneously delivers gene-silencing molecules to cancer cells AND activates the immune system against the tumor. This dual-function design means the delivery vehicle itself becomes part of the therapeutic effect, potentially making the overall treatment more potent.

What is EMP2 and why target it in breast cancer?

Epithelial membrane protein 2 (EMP2) is a protein that helps cancer cells grow, migrate, and invade surrounding tissues. By silencing EMP2 with siRNA (a molecule that blocks the gene's expression), the researchers could suppress breast cancer cell migration and invasion. Combined with the peptide's immune-boosting properties, this creates a two-pronged attack: directly weakening cancer cells while strengthening the body's immune defenses against them.

Read the original research

Cholesterol modified defense peptide as an EMP2-siRNA delivery system for synergistic immunogene therapy against breast cancer.

Materials today. Bio, 35, 102321

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Xiaoyun; Chen, Siliang; He, Gu; Zhu, Yanghui; Zhang, Nan; Gong, Changyang; Li, Xiang; Chen, Yujuan. (2025). Cholesterol modified defense peptide as an EMP2-siRNA delivery system for synergistic immunogene therapy against breast cancer.. Materials today. Bio, 35, 102321. https://doi.org/10.1016/j.mtbio.2025.102321